PowersWJRabinsteinAAAckersonT, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211
3.
KobeissiHGhozySTurfeB, et al. Tenecteplase vs. Alteplase for treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized trials. Front Neurol. 2023;14:1102463. doi:10.3389/fneur.2023.1102463
4.
NguyenCPLahrMMvan der ZeeDJ, et al. Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke. Eur Stroke J. 2023;8(3):638-646. doi:10.1177/23969873231174943
5.
MenonBKBuckBHSinghN, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400(10347):161-169. doi:10.1016/S0140-6736(22)01054-6
6.
KvistadCENæssHHellebergBH, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022;21(6):511-519. doi:10.1016/S1474-4422(22)00124-7
7.
ParsonsMSprattNBivardA, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099-1107. doi:10.1056/NEJMoa1109842
8.
DiedlerJAhmedNGlahnJ, et al. Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg. Stroke. 2011;42(6):1615-1620. doi:10.1161/STROKEAHA.110.603514
